Overall CDXC gets a fundamental rating of 6 out of 10. We evaluated CDXC against 58 industry peers in the Life Sciences Tools & Services industry. CDXC has an excellent financial health rating, but there are some minor concerns on its profitability. CDXC is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CDXC was profitable.
CDXC had a positive operating cash flow in the past year.
In the past 5 years CDXC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CDXC reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of 12.52%, CDXC belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
The Return On Equity of CDXC (18.55%) is better than 90.91% of its industry peers.
The Return On Invested Capital of CDXC (12.13%) is better than 89.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	12.52%
ROE	18.55%
ROIC	12.13%

ROA(3y)-9.02%

ROA(5y)-25.18%

ROE(3y)-18.83%

ROE(5y)-52.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of CDXC (8.58%) is better than 74.55% of its industry peers.
Looking at the Operating Margin, with a value of 7.76%, CDXC is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
CDXC has a Gross Margin of 61.84%. This is amongst the best in the industry. CDXC outperforms 87.27% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.

		Industry Rank	Sector Rank
OM	7.76%
PM (TTM)	8.58%
GM	61.84%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y2.12%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CDXC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
CDXC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CDXC has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 15.46 indicates that CDXC is not in any danger for bankruptcy at the moment.
CDXC's Altman-Z score of 15.46 is amongst the best of the industry. CDXC outperforms 100.00% of its industry peers.
There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	15.46

ROIC/WACC1.11

WACC10.97%

2.3 Liquidity

CDXC has a Current Ratio of 3.57. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.57, CDXC perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
CDXC's Quick ratio of 3.06 is in line compared to the rest of the industry. CDXC outperforms 58.18% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.57
Quick Ratio	3.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CDXC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 242.86%, which is quite impressive.
The Revenue has grown by 19.17% in the past year. This is quite good.
CDXC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.

EPS 1Y (TTM)242.86%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5733.33%

Revenue 1Y (TTM)19.17%

Revenue growth 3Y13.87%

Revenue growth 5Y16.56%

Sales Q2Q%37.41%

3.2 Future

The Earnings Per Share is expected to grow by 43.55% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.24% on average over the next years. This is quite good.

EPS Next Y19%

EPS Next 2Y41.63%

EPS Next 3Y43.55%

EPS Next 5YN/A

Revenue Next Year20.72%

Revenue Next 2Y18.22%

Revenue Next 3Y19.24%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 78.70, the valuation of CDXC can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.21. CDXC is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 66.13, the valuation of CDXC can be described as expensive.
CDXC's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 25.98, CDXC is valued quite expensively.

		Industry Rank	Sector Rank
PE	78.7
Fwd PE	66.13

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CDXC is valued a bit cheaper than the industry average as 61.82% of the companies are valued more expensively.
65.45% of the companies in the same industry are more expensive than CDXC, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	51.22
EV/EBITDA	66.44

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDXC does not grow enough to justify the current Price/Earnings ratio.
CDXC has a very decent profitability rating, which may justify a higher PE ratio.
CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.